AVeRT: Anti-PD-1 Monoclonal Antibody (Nivolumab) in Combination With DC Vaccines for the Treatment of Recurrent Grade III and Grade IV Brain Tumors

Trial Profile

AVeRT: Anti-PD-1 Monoclonal Antibody (Nivolumab) in Combination With DC Vaccines for the Treatment of Recurrent Grade III and Grade IV Brain Tumors

Discontinued
Phase of Trial: Phase I

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Nivolumab (Primary) ; Dendritic cell vaccines
  • Indications Glioma
  • Focus Adverse reactions
  • Acronyms AVERT
  • Most Recent Events

    • 28 Sep 2017 Planned End Date changed from 1 Aug 2019 to 1 Sep 2018.
    • 28 Sep 2017 Status changed from recruiting to discontinued.
    • 08 Feb 2016 Planned primary completion date changed from 1 Dec 2017 to 1 May 2018 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top